These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://andrewzdma538193.blogunok.com/39334046/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide